Abstract. Epidermal growth factor receptor (EGFR) gene mutations are associated with the sensitivity of non-small cell lung carcinomas (NSCLCs) to gefitinib, but such findings have not been reported in squamous cell carcinomas of the head and heck (SCCHNs). Accordingly, we determined whether EGFR gene expression and mutations correlate with the in vitro efficacy of gefitinib in SCCHN cell lines. EGFR status was analyzed in 16 different SCCHN cell lines by polymerase chain reaction (PCR) and direct sequencing for activating mutations, by real-time quantitative RT-PCR, and by Western blot analysis for RNA and protein expression. Using direct sequencing of PCR products from exons 18-23 of 9 SCCHN cell lines, we found a heterozygous EGFR mutation (EGFR mut ) with a 2607G›A transition in exon 20 (G/A genotype). The 9 different cell lines that showed this mutation also showed higher sensitivity (lower IC 50 values) to gefitinib than cell lines with wild-type EGFR (EGFR wt : G/G genotype) (p=0.016). EGFR protein levels correlated robustly (r=0.76) and significantly (p=0.0007) with EGFR mRNA levels and with IC 50 values for gefitinib (r=0.65, p=0.0067). EGFR mRNA correlated with IC 50 values (r=0.67, p=0.0046). Our conclusion was that the heterozygous and synonymous transition of the EGFR gene and low EGFR expression levels of mRNA and protein in SCCHN may be reliable predictors of high sensitivity in SCCHN patients to gefitinib.
Introduction
Epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane glycoprotein receptor which exhibits a tyrosine kinase activity that regulates cell growth. EGFR overexpression has been frequently observed in squamous cell carcinomas of the head and neck (SCCHNs) and is thought to be involved in carcinogenesis and metastasis. Moreover, EGFR overexpression correlates with tumor size, clinical stage and poor prognosis (1) (2) (3) (4) . EGFR signaling has been found to control not only cell growth, but also angiogenesis and DNA repair (5, 6) , and has recently been assessed as a molecular target in the treatment of SCCHN.
Gefitinib (ZD1839, Iressa ® ), a low-molecular-weight anilinoquinazoline, is an orally active agent that reversibly inhibits EGFR tyrosine kinase activity. It has an acceptable toxicity profile and promising clinical efficacy in SCCHN patients in Phase I and II trials (7) (8) (9) (10) . Gefitinib is expected to be efficacious in non-small cell lung carcinoma (NSCLC) patients with high levels of EGFR expression because EGFR is also overexpressed in a significant portion of NSCLCs (11, 12) . However, results from clinical trials on the treatment of NSCLC with gefitinib have been varied and not statistically significant (13) (14) (15) . A potential molecular mechanism underlying this variable clinical response is suggested by recent reports showing that kinase domain mutations of the EGFR gene in NSCLC tissues predict clinical responses to gefitinib (16, 17) .
In the present study, we determined whether EGFR gene expression and mutations correlate with in vitro efficacy of gefitinib in SCCHN cells.
Materials and methods
Reagents. Gefitinib was a gift from Astra-Zeneca Pharmaceuticals (Macclesfield, UK). RPMI-1640 was purchased from Nissui (Tokyo, Japan). Enhanced chemiluminescence (ECL) assay kits were from Amersham Biosciences (Piscataway, NJ). Protein assay kits were from Bio-Rad (Richmond, CA). SepaGene DNA purification kits were from Sanko Junyaku (Tokyo, Japan Detection of EGFR mutations. Genomic DNA was extracted using a SepaGene kit. Exons 18-23 of the EGFR gene were amplified by polymerase chain reaction (PCR) using the specific primer sets listed in Table I ( 16) . The PCR products were further analyzed by direct nucleotide sequencing using ABI PRISM 3100 DNA Analyzer (Applied Biosystems) in order to detect mutations.
Growth inhibition assay. Cells were seeded in 96-well plates at 1x10 4 cells/well in 100 μl of medium. Twenty-four h after seeding, cells were treated with various concentrations of gefitinib for 24 h. The inhibition of cell growth was assessed using the MTT colorimetric assay. Relative growth inhibition rates for the vehicle control were calculated and IC 50 values were determined as the drug concentrations associated with 50% survival of cells.
Real-time quantitative RT-PCR.
Total-RNA was extracted using Isogen RNA extraction kits according to the manu- Table I . Primer sets for EGFR mutation analysis. 
facturer's protocol. Total-RNA (1 μg) was converted into cDNA using Takara RNA PCR Kits (AMV) Version 3.0. Real-time quantitative RT-PCR was carried out according to a fluorescence detection method using the TaqMan PCR Reagent kit or SYBG-based real-time PCR kit with specific primers, as shown in Table II . PCR was conducted using the following cycle parameters: 50˚C for 2 min and 95˚C for 10 min followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min.
Data analysis of quantitative RT-PCR.
The threshold cycle (C T ) value of a target gene was divided by the endogenous reference (ß-actin) C T value to correct for the input amount of cDNA. All corrected quantities were expressed as an n-fold difference relative to the gene expression levels of KB cells as the reference.
Results

Expression of EGFR protein and mRNA in SCCHN cell lines.
We analyzed the expression of EGFR protein in 16 different SCCHN cell lines by Western blots (Fig. 1, Table III ). Expression levels of EGFR protein in each cell line were determined by densitometry and by relative expression levels in comparison with the expression level of ß-actin. EGFR protein was detectable in all cell lines tested; levels were higher in KCC-T873 and YCU-T892 than in the A431 (positive control) cells.
Using real-time quantitative RT-PCR, we analyzed steady state levels of EGFR mRNA in 16 different SCCHN cell lines (Table III) . EGFR mRNA was detected in all the cell lines tested. The steady state level of EGFR mRNA was highest in KCC-T873 cells and lowest in KCC-M871 cells, with the difference being >100-fold. 50 values of gefitinib with EGFR expression and mutation. The drug concentrations, or IC 50 values, used in each cell line and resulting in a 50% inhibition of cell growth are shown in Table III . KCC-MS871, KCC-TCM901 and KCC-T871 were the most sensitive to gefitinib, with IC 50 values of 41.6, 43.9 and 44.4 μM, respectively.
Comparison of IC
Linear regression showed that, across cell lines, EGFR protein levels correlated robustly with EGFR mRNA levels (r=0.76, p=0.0007; Fig. 2A ) and with IC 50 values of gefitinib (r=0.65, p=0.0067; Fig. 2B ). Steady state levels of EGFR mRNA also correlated robustly with IC 50 values of gefitinib (r=0.67, p=0.0046; Fig. 2C ). Although we found duplex bands of EGFR protein in some cases (see Fig. 5 ), EGFR protein levels did not have a significant correlation with any other parameters, including IC 50 values.
Through the direct sequencing of PCR products from exons 18-23 of 9 SCCHN cell lines, we found a heterozygous EGFR mutation with a 2607G›A transition (EGFRmut) in exon 20. 
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This transition was synonymous (Q787Q) and identified with a known single nucleotide polymorphism (SNP) (rs1050171 in the NCBI SNP database) (Fig. 3, Table IV ). We then compared the frequencies of the EGFR gene genotype with the IC 50 values of gefitinib (Fig. 4) . The heterozygous EGFRmut (2607G›A; G/A genotype) group, which was found in 9 different cell lines, showed a higher sensitivity (lower IC 50 value) to gefitinib than did cell lines with wild-type EGFR (EGFRwt; G/G genotype) (p=0.016; Fig. 4C ). However, differences in EGFR protein or mRNA expression levels were not significant between the G/G and G/A genotypes ( Fig. 4A and B) . 
Effects of gefitinib on signaling downstream of EGFR.
We examined the effects of gefitinib on the phosphorylation of EGFR, STAT3 and p42/p44 MAP kinase in 5 representative cell lines carrying EGFRwt (YCU-M862, YCU-MS861 and KCC-T873 cells) and heterozygous EGFRmut (GA genotype) (KCC-MS871 and KCC-TCM901 cells) (Fig. 5) . Regardless of genotype, EGFR was phosphorylated by EGF stimulation within 24 h. Its phosphorylation was significantly suppressed by gefitinib treatment in all 5 cell lines. STAT3 phosphorylation by EGF stimulation at 50 μg/ml was only seen in the GG genotype cell line, YCU-M862, and this activation was inhibited by gefitinib. In the other 4 cell lines, STAT3 was constitutively active. This activation was not altered by either EGF and/or gefitinib treatment. p44/42 MAP kinase was phosphorylated by the stimulation of EGF. This phosphorylation was decreased by gefitinib treatment in all 5 cell lines. However, in the G/A genotype cell line KCC-TCM901, the inhibitory effect of gefitinib on MAP kinase phosphorylation was weak. As shown in Table III , the IC 50 values of gefitinib in YCU-M862 cells (remarkable downregulation of STAT3 phosphorylation by gefitinib) and KCC-TCM901 cells (insensitive to the MAP kinasephosphorylation-inhibitory activity of gefitinib) were 66.3 and 43.9 μM, respectively. These data suggest that the inhibition of phosphorylated levels of p44/42 MAP kinase and STAT3 after gefitinib treatment are not predictors of a response to gefitinib.
Discussion
In earlier studies, the efficacy of gefitinib was thought to depend on EGFR expression levels in NSCLCs as compared to adjacent normal cells (12, 20) . However, this concept has recently been negated in other clinical trials. The most recent study showed that EGFR protein levels did not differ between SCCs and adenocarcinomas in lung cancer and that there were no significant correlations between EGFR expression and gefitinib IC 50 values (21) . Moreover, the report showed that NSCLC cell lines with high copy numbers of the EGFR gene were more sensitive to gefitinib treatment, and suggested that high copy numbers of EGFR are a benefit in gefitinib treatment (21) .
Unlike studies on cell lines from lung cancers, the present study showed an association between expression levels of Table IV . Mutation in tyrosine kinase domain of EGFR. EGFR protein and gefitinib IC 50 in cell lines from SCCHNs. However, we also showed that even SCCHN cell lines that are sensitive to gefitinib require higher concentrations (higher IC 50 values) than those reported for NSCLC (22) . This suggests that, in order to show clinical efficacy, the dose for patients with SCCHN might need to be higher than the approved dose (250 mg/day) for patients with NSCLC.
Several articles have revealed molecular mechanisms in which EGFR gene mutations are associated with altered sensitivity to gefitinib in NSCLCs (16, 23, 24) . Mutations of the EGFR gene in the tyrosine kinase domain at exons 18-21 are one of the critical factors of gefitinib response in NSCLC (25) . Of these mutations, 86% were found in 2 hotspot regions, exons 19 and 21, with the remaining 14% scattered throughout exons 18-21, whereas in SCCHNs it has been reported that EGFR mutations are predominant in exon 19 (22, 26) . EGFR mutations in the tyrosine kinase domain were common in Asian patients (7.3%) (26) and rare in Caucasian patients (1%) (22) . We observed an SNP in exon 20 of 9/16 SCCHN cell lines tested (56.3%). This SNP, listed in the NCBI SNP database as rs1050171, is located in the EGFR tyrosine kinase domain. Due to a synonymous transition (Q787Q), it has been considered a silent mutation. The current frequencies of the genotype at this position are: European, A/A (37.5%), A/G (45.8%), G/G (16.7%); Asian, A/A (4.2%), A/G (20.8%) , G/G (75.0%) (NCBI database, rs1050171). The efficacy of gefitinib against SCCHN in Caucasians is not significantly different than it is in Asians, although this genotype has a higher incidence of occurence in Europe. The presence of this SNP (G/A genotype) is therefore limited. However, it may be a beneficial parameter in Asian patients with SCCHN since, in the present study, the heterozygous EGFRmut (G/A genotype) group showed higher sensitivity (lower IC 50 values) to gefitinib than the EGFRwt (G/G genotype) group did. Dominant mutations observed in NSCLCs were the deletion of 2-15 nucleotides between codon E740 and 753 in exon 19, e.g., delE747_E749 and delE746_A750, and a point mutation, L858R, in exon 21 (25) . These mutations increase the tyrosine kinase inhibitory activity of gefitinib due to conformational changes at the ATP-binding site. However, they were rare in SCCHNs in both our study and those of others (26) . Our data show a good correlation between synonymous mutations (Q787Q) and response to gefitinib. It is thought that synonymous mutation Q787Q may not be 'silent', but may in fact result in abnormal splicing. For example, in Marfan syndrome a synonymous amino acid substitution (Q508Q) of TGFBR2 (transforming growth factor-ß receptor 2) has been reported to occur because of abnormal splicing (27) . The tau gene, whose encoded protein is associated with microtubule formation, has an S305S silent mutation which causes progressive supranuclear palsy pathology (28). In some of the SCCHN cell lines tested in the present study, we found duplexes in the anti-EGFR antibody-reactive band. However, this alteration was not strongly correlated with either the frequency of the synonymous mutation or with the response to gefitinib. Alternatively, a synonymous mutation may affect the half-life of EGFR mRNA or EGFR turnover. Further studies are needed to clarify the effects of Q787Q mutations on the production of abnormal splicing variants.
In conclusion, we found that high expression levels of EGFR mRNA and protein are associated with low sensitivity to gefitinib. Furthermore, cell lines with heterozygous and synonymous transitions of the EGFR gene (Q787Q, rs1050171 (NCBI SNP database) have a significantly higher sensitivity to gefitinib than do EGFRwt cell lines. Thus, our data suggest new advantages in molecular-targeting therapy using gefitinib for selected patients with SCCHN.
